Skip to main content
Premium Trial:

Request an Annual Quote

Somalogic Launches Validation Studies of Protein Biomarkers for Pancreatic Cancer and Mesothelioma

Premium

By Adam Bonislawski

Clinical proteomics firm Somalogic has begun validation of its protein biomarker-based diagnostics for pancreatic cancer and mesothelioma.

For each test – both of which employ roughly a dozen proteins detected using the company's Somamer detection platform – Somalogic is planning trials on the order of 400 patients, which it expects to finish within a year, clinical research director Rachel Ostroff told ProteoMonitor.

The pancreatic cancer panel – to which Quest Diagnostics has the commercial rights – is aimed at two clinical indications. The first, Ostroff said, is as a screening test in high-risk populations, such as "people with a family history or known genetic predisposition or people who have high levels of smoking and alcohol use."

The second use is as a differential diagnostic to help physicians determine whether a patient showing symptoms consistent with pancreatic cancer does, in fact, have the disease.

The panel will be adapted for each indication by varying the decision thresholds according to the intended use, Ostroff said. In the case of the screening test, specificity will be maximized to avoid false positives that could lead to unnecessary biopsies. In the case of the differential diagnostic, sensitivity will be maximized given that patients presenting symptoms would likely be moved on for additional procedures regardless.

Ostroff said that given the rarity of pancreatic cancer in even high-risk populations, the screening test would need a specificity of approximately 98 percent to be useful. In data presented at last month's American Association for Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development, the pancreatic cancer panel showed specificity of 97 percent and sensitivity of 66 percent. Adjusted for differential diagnoses purposes, it demonstrated sensitivity of 92 percent and specificity of 60 percent.

The company also presented data showing that its mesothelioma panel demonstrated 100 percent specificity with 80 percent sensitivity. Somalogic is currently exploring commercialization strategies including possible partnerships for this diagnostic, director of corporate strategy Mark Messenbaugh told ProteoMonitor.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.